| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 25 | 2024 | 290 | 4.770 |
Why?
|
| Influenza, Human | 23 | 2024 | 282 | 4.670 |
Why?
|
| Humans | 265 | 2024 | 18430 | 2.780 |
Why?
|
| Vaccination | 43 | 2024 | 674 | 2.560 |
Why?
|
| Hospitalization | 38 | 2024 | 847 | 2.380 |
Why?
|
| Propensity Score | 9 | 2020 | 94 | 1.810 |
Why?
|
| Product Surveillance, Postmarketing | 15 | 2020 | 110 | 1.790 |
Why?
|
| Research Design | 13 | 2024 | 402 | 1.780 |
Why?
|
| Male | 149 | 2024 | 10440 | 1.770 |
Why?
|
| Female | 163 | 2024 | 13136 | 1.700 |
Why?
|
| Proportional Hazards Models | 16 | 2023 | 743 | 1.630 |
Why?
|
| Adult | 119 | 2024 | 7910 | 1.600 |
Why?
|
| California | 89 | 2024 | 2365 | 1.580 |
Why?
|
| Bias | 9 | 2024 | 111 | 1.520 |
Why?
|
| Health Maintenance Organizations | 33 | 2013 | 479 | 1.480 |
Why?
|
| Aged | 91 | 2024 | 6417 | 1.410 |
Why?
|
| Cohort Studies | 48 | 2023 | 2672 | 1.400 |
Why?
|
| Pneumococcal Vaccines | 13 | 2020 | 80 | 1.380 |
Why?
|
| Middle Aged | 104 | 2024 | 8284 | 1.330 |
Why?
|
| Adolescent | 72 | 2024 | 3798 | 1.220 |
Why?
|
| Emergency Service, Hospital | 19 | 2024 | 382 | 1.220 |
Why?
|
| Vaccines | 11 | 2023 | 222 | 1.210 |
Why?
|
| Pneumococcal Infections | 11 | 2016 | 53 | 1.180 |
Why?
|
| Whooping Cough | 9 | 2022 | 75 | 1.170 |
Why?
|
| Adamantane | 3 | 2017 | 6 | 1.100 |
Why?
|
| Dipeptides | 3 | 2017 | 6 | 1.100 |
Why?
|
| Child | 52 | 2024 | 2571 | 1.080 |
Why?
|
| Chickenpox Vaccine | 10 | 2022 | 101 | 1.060 |
Why?
|
| Ambulatory Care | 10 | 2024 | 266 | 1.040 |
Why?
|
| United States | 44 | 2024 | 4164 | 1.010 |
Why?
|
| Infant | 49 | 2024 | 1245 | 1.010 |
Why?
|
| Young Adult | 37 | 2024 | 2518 | 1.000 |
Why?
|
| Child, Preschool | 45 | 2024 | 1478 | 1.000 |
Why?
|
| Confounding Factors (Epidemiology) | 12 | 2016 | 99 | 0.980 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 9 | 2022 | 116 | 0.930 |
Why?
|
| Immunization | 6 | 2015 | 80 | 0.930 |
Why?
|
| Case-Control Studies | 23 | 2023 | 1173 | 0.930 |
Why?
|
| Retrospective Studies | 42 | 2024 | 2550 | 0.910 |
Why?
|
| Seizures, Febrile | 5 | 2022 | 47 | 0.910 |
Why?
|
| Colorectal Neoplasms | 9 | 2022 | 656 | 0.880 |
Why?
|
| Hypoglycemic Agents | 10 | 2017 | 288 | 0.880 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 9 | 2020 | 95 | 0.870 |
Why?
|
| Aged, 80 and over | 31 | 2024 | 2003 | 0.870 |
Why?
|
| Meningococcal Vaccines | 7 | 2006 | 46 | 0.870 |
Why?
|
| Myocarditis | 4 | 2022 | 18 | 0.830 |
Why?
|
| Adenoma | 6 | 2022 | 100 | 0.800 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2017 | 8 | 0.800 |
Why?
|
| Incidence | 27 | 2024 | 1314 | 0.780 |
Why?
|
| Health Care Costs | 11 | 2012 | 251 | 0.780 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 4 | 0.760 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2023 | 142 | 0.750 |
Why?
|
| Time Factors | 25 | 2022 | 1136 | 0.750 |
Why?
|
| Colonoscopy | 7 | 2022 | 268 | 0.740 |
Why?
|
| Myocardial Infarction | 10 | 2017 | 249 | 0.740 |
Why?
|
| Cost Sharing | 9 | 2017 | 40 | 0.700 |
Why?
|
| Risk Factors | 37 | 2024 | 3449 | 0.690 |
Why?
|
| Vaccines, Combined | 11 | 2023 | 91 | 0.690 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 5 | 2022 | 67 | 0.670 |
Why?
|
| Outcome and Process Assessment (Health Care) | 6 | 2016 | 110 | 0.670 |
Why?
|
| Computer Simulation | 5 | 2024 | 85 | 0.660 |
Why?
|
| Patient Safety | 2 | 2015 | 41 | 0.640 |
Why?
|
| Pericarditis | 3 | 2022 | 14 | 0.620 |
Why?
|
| Electronic Health Records | 11 | 2023 | 747 | 0.600 |
Why?
|
| Insurance, Health | 9 | 2021 | 217 | 0.590 |
Why?
|
| Sitagliptin Phosphate | 2 | 2017 | 5 | 0.590 |
Why?
|
| Vaccines, Synthetic | 10 | 2024 | 43 | 0.580 |
Why?
|
| Vaccination Coverage | 4 | 2021 | 45 | 0.580 |
Why?
|
| Herpes Zoster | 5 | 2023 | 88 | 0.570 |
Why?
|
| Herpes Zoster Vaccine | 4 | 2023 | 64 | 0.560 |
Why?
|
| Quality Indicators, Health Care | 5 | 2010 | 197 | 0.550 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2019 | 342 | 0.550 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 68 | 0.550 |
Why?
|
| Follow-Up Studies | 23 | 2020 | 1269 | 0.540 |
Why?
|
| Neoplasms | 7 | 2000 | 457 | 0.530 |
Why?
|
| Early Detection of Cancer | 7 | 2022 | 526 | 0.530 |
Why?
|
| Guillain-Barre Syndrome | 4 | 2022 | 19 | 0.530 |
Why?
|
| Hemorrhage | 1 | 2016 | 63 | 0.520 |
Why?
|
| Respiratory Tract Infections | 4 | 2022 | 54 | 0.520 |
Why?
|
| Quality Assurance, Health Care | 4 | 2010 | 188 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2022 | 350 | 0.500 |
Why?
|
| Medicare Part D | 5 | 2016 | 21 | 0.490 |
Why?
|
| Cardiovascular Diseases | 8 | 2018 | 630 | 0.470 |
Why?
|
| Seasons | 7 | 2024 | 105 | 0.460 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 7 | 2016 | 101 | 0.460 |
Why?
|
| Haemophilus Vaccines | 8 | 2020 | 25 | 0.460 |
Why?
|
| Risk Assessment | 16 | 2019 | 1143 | 0.450 |
Why?
|
| Autistic Disorder | 5 | 2017 | 105 | 0.450 |
Why?
|
| Diabetes Mellitus | 9 | 2020 | 530 | 0.440 |
Why?
|
| Immunization Schedule | 11 | 2021 | 133 | 0.440 |
Why?
|
| Pregnancy | 15 | 2023 | 1516 | 0.440 |
Why?
|
| Primary Health Care | 10 | 2016 | 848 | 0.440 |
Why?
|
| Databases, Factual | 11 | 2020 | 327 | 0.440 |
Why?
|
| RNA, Messenger | 8 | 2023 | 80 | 0.420 |
Why?
|
| Logistic Models | 16 | 2020 | 962 | 0.420 |
Why?
|
| Chronic Disease | 12 | 2016 | 468 | 0.420 |
Why?
|
| Critical Illness | 2 | 2023 | 53 | 0.420 |
Why?
|
| Clinical Competence | 2 | 2010 | 108 | 0.420 |
Why?
|
| Health Expenditures | 5 | 2018 | 82 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 142 | 0.400 |
Why?
|
| Neuralgia, Postherpetic | 2 | 2023 | 15 | 0.390 |
Why?
|
| Managed Care Programs | 7 | 2013 | 347 | 0.390 |
Why?
|
| Outcome Assessment (Health Care) | 10 | 2013 | 254 | 0.390 |
Why?
|
| Disease Susceptibility | 4 | 2020 | 46 | 0.380 |
Why?
|
| Patient Care Team | 3 | 2003 | 127 | 0.380 |
Why?
|
| Infant, Newborn | 16 | 2024 | 872 | 0.370 |
Why?
|
| Heart Failure | 1 | 2016 | 398 | 0.370 |
Why?
|
| Regression Analysis | 9 | 2018 | 319 | 0.360 |
Why?
|
| Depressive Disorder | 4 | 2012 | 231 | 0.360 |
Why?
|
| Risk | 17 | 2020 | 552 | 0.360 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 197 | 0.350 |
Why?
|
| Fever | 5 | 2022 | 60 | 0.340 |
Why?
|
| Epidemiologic Research Design | 4 | 2016 | 24 | 0.330 |
Why?
|
| Hypothyroidism | 2 | 2004 | 8 | 0.330 |
Why?
|
| Pregnancy Outcome | 4 | 2017 | 159 | 0.320 |
Why?
|
| Pertussis Vaccine | 3 | 2013 | 17 | 0.320 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 5 | 2024 | 56 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 177 | 0.320 |
Why?
|
| Antidepressive Agents | 5 | 2012 | 162 | 0.320 |
Why?
|
| Age Factors | 12 | 2014 | 965 | 0.320 |
Why?
|
| Dysentery | 1 | 2008 | 2 | 0.310 |
Why?
|
| Measles | 2 | 2022 | 26 | 0.310 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 42 | 0.300 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2008 | 14 | 0.300 |
Why?
|
| Clostridium difficile | 1 | 2008 | 23 | 0.300 |
Why?
|
| Cross Infection | 1 | 2008 | 28 | 0.300 |
Why?
|
| Bacteremia | 3 | 2004 | 15 | 0.300 |
Why?
|
| Abortion, Spontaneous | 3 | 2017 | 52 | 0.300 |
Why?
|
| Delivery of Health Care, Integrated | 9 | 2024 | 567 | 0.300 |
Why?
|
| Measles Vaccine | 4 | 2022 | 21 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2016 | 760 | 0.300 |
Why?
|
| Insurance Selection Bias | 3 | 2018 | 5 | 0.290 |
Why?
|
| Prospective Studies | 13 | 2020 | 1314 | 0.290 |
Why?
|
| Chickenpox | 3 | 2014 | 38 | 0.290 |
Why?
|
| Autoimmune Diseases | 3 | 2015 | 23 | 0.290 |
Why?
|
| Bacterial Vaccines | 7 | 2002 | 17 | 0.290 |
Why?
|
| SEER Program | 5 | 2017 | 101 | 0.280 |
Why?
|
| Drug Approval | 2 | 2020 | 14 | 0.280 |
Why?
|
| Vaccines, Inactivated | 4 | 2023 | 70 | 0.280 |
Why?
|
| Surveys and Questionnaires | 13 | 2020 | 1389 | 0.280 |
Why?
|
| Models, Theoretical | 2 | 2020 | 76 | 0.270 |
Why?
|
| Otitis Media | 3 | 2003 | 21 | 0.270 |
Why?
|
| Cluster Analysis | 4 | 2023 | 96 | 0.270 |
Why?
|
| Comparative Effectiveness Research | 4 | 2015 | 77 | 0.270 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2016 | 8 | 0.270 |
Why?
|
| Odds Ratio | 10 | 2023 | 701 | 0.270 |
Why?
|
| Asthma | 3 | 2018 | 390 | 0.270 |
Why?
|
| Autism Spectrum Disorder | 2 | 2022 | 164 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2016 | 34 | 0.260 |
Why?
|
| Patient Compliance | 4 | 2009 | 318 | 0.260 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2004 | 74 | 0.260 |
Why?
|
| Immunization, Secondary | 7 | 2022 | 64 | 0.260 |
Why?
|
| Selection Bias | 5 | 2015 | 24 | 0.260 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 7 | 2016 | 30 | 0.260 |
Why?
|
| Multivariate Analysis | 10 | 2018 | 598 | 0.250 |
Why?
|
| Pain | 4 | 2011 | 84 | 0.250 |
Why?
|
| Choristoma | 1 | 2004 | 1 | 0.250 |
Why?
|
| Congenital Hypothyroidism | 1 | 2004 | 1 | 0.250 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 1 | 0.250 |
Why?
|
| Fee-for-Service Plans | 3 | 1999 | 28 | 0.250 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2001 | 2 | 0.250 |
Why?
|
| Thyroid Gland | 1 | 2004 | 5 | 0.250 |
Why?
|
| Pneumonia | 5 | 2010 | 56 | 0.250 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2024 | 3 | 0.250 |
Why?
|
| Insurance Coverage | 4 | 2018 | 136 | 0.250 |
Why?
|
| Cost Control | 1 | 2004 | 25 | 0.250 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 7 | 2009 | 22 | 0.250 |
Why?
|
| Quality of Health Care | 3 | 2004 | 347 | 0.240 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2024 | 24 | 0.240 |
Why?
|
| Gonorrhea | 1 | 2024 | 19 | 0.240 |
Why?
|
| Chlamydia Infections | 1 | 2024 | 27 | 0.240 |
Why?
|
| Drug Prescriptions | 3 | 2022 | 157 | 0.230 |
Why?
|
| Antipsychotic Agents | 2 | 2016 | 57 | 0.230 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 20 | 0.230 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2023 | 2 | 0.230 |
Why?
|
| Glycated Hemoglobin A | 4 | 2020 | 233 | 0.230 |
Why?
|
| Disease Management | 1 | 2004 | 143 | 0.230 |
Why?
|
| Mental Disorders | 7 | 2005 | 295 | 0.230 |
Why?
|
| Drug Therapy | 3 | 2015 | 21 | 0.230 |
Why?
|
| Viral Vaccines | 2 | 2023 | 15 | 0.230 |
Why?
|
| Telephone | 4 | 2015 | 179 | 0.220 |
Why?
|
| Prevalence | 10 | 2015 | 911 | 0.220 |
Why?
|
| Risk Adjustment | 3 | 2013 | 32 | 0.220 |
Why?
|
| Prenatal Care | 3 | 2020 | 134 | 0.220 |
Why?
|
| Urticaria | 1 | 2022 | 3 | 0.220 |
Why?
|
| Exanthema | 1 | 2022 | 8 | 0.220 |
Why?
|
| Pharyngitis | 1 | 2022 | 11 | 0.210 |
Why?
|
| Patient Satisfaction | 7 | 2012 | 232 | 0.210 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 14 | 0.210 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2018 | 40 | 0.210 |
Why?
|
| Lithium | 2 | 2017 | 3 | 0.210 |
Why?
|
| Melanoma | 2 | 2017 | 37 | 0.210 |
Why?
|
| Models, Statistical | 3 | 2013 | 185 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 6 | 2016 | 25 | 0.210 |
Why?
|
| Hepatitis B Vaccines | 3 | 2012 | 46 | 0.210 |
Why?
|
| Observational Studies as Topic | 2 | 2019 | 49 | 0.200 |
Why?
|
| Vaccines, Conjugate | 7 | 2006 | 66 | 0.200 |
Why?
|
| Cost of Illness | 2 | 2007 | 100 | 0.200 |
Why?
|
| Sulfonylurea Compounds | 3 | 2017 | 28 | 0.200 |
Why?
|
| Skin Neoplasms | 2 | 2017 | 64 | 0.200 |
Why?
|
| Mammography | 2 | 2016 | 174 | 0.200 |
Why?
|
| Sensitivity and Specificity | 9 | 2019 | 321 | 0.200 |
Why?
|
| Central Nervous System Stimulants | 2 | 2011 | 29 | 0.200 |
Why?
|
| Confidence Intervals | 8 | 2016 | 253 | 0.200 |
Why?
|
| Disease Outbreaks | 3 | 2017 | 39 | 0.190 |
Why?
|
| Comorbidity | 9 | 2022 | 619 | 0.190 |
Why?
|
| Medication Adherence | 3 | 2020 | 267 | 0.190 |
Why?
|
| Age Distribution | 7 | 2013 | 261 | 0.190 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 70 | 0.190 |
Why?
|
| Data Collection | 2 | 2020 | 275 | 0.190 |
Why?
|
| Patient Care Management | 2 | 2012 | 32 | 0.190 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2018 | 51 | 0.180 |
Why?
|
| Blood Glucose | 3 | 2013 | 346 | 0.180 |
Why?
|
| Health Insurance Exchanges | 2 | 2018 | 5 | 0.180 |
Why?
|
| Vaccination Refusal | 1 | 2020 | 10 | 0.180 |
Why?
|
| Health Services Research | 5 | 2014 | 264 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 31 | 0.180 |
Why?
|
| Eggs | 1 | 2020 | 9 | 0.180 |
Why?
|
| Influenza A virus | 1 | 2020 | 14 | 0.180 |
Why?
|
| Family Practice | 1 | 2020 | 53 | 0.180 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 83 | 0.180 |
Why?
|
| European Continental Ancestry Group | 3 | 2009 | 554 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2019 | 1296 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2020 | 25 | 0.170 |
Why?
|
| Models, Biological | 1 | 2019 | 32 | 0.170 |
Why?
|
| Bacterial Proteins | 5 | 2002 | 18 | 0.170 |
Why?
|
| Depression | 3 | 2015 | 518 | 0.170 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 42 | 0.170 |
Why?
|
| Pharmacoepidemiology | 3 | 2015 | 22 | 0.170 |
Why?
|
| Patient Portals | 1 | 2020 | 25 | 0.170 |
Why?
|
| Thiazolidinediones | 2 | 2017 | 54 | 0.170 |
Why?
|
| Hospital Mortality | 5 | 2023 | 150 | 0.170 |
Why?
|
| Coronary Disease | 2 | 2006 | 185 | 0.170 |
Why?
|
| Occult Blood | 2 | 2018 | 167 | 0.170 |
Why?
|
| Sex Distribution | 6 | 2013 | 198 | 0.170 |
Why?
|
| Medicare | 6 | 2016 | 214 | 0.170 |
Why?
|
| Office Visits | 2 | 2013 | 86 | 0.160 |
Why?
|
| Hypertension | 7 | 2010 | 524 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 119 | 0.160 |
Why?
|
| Crohn Disease | 2 | 2009 | 16 | 0.160 |
Why?
|
| Herpesvirus 3, Human | 4 | 2023 | 49 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 69 | 0.160 |
Why?
|
| Drug Utilization | 3 | 2008 | 134 | 0.160 |
Why?
|
| Pediatrics | 1 | 2020 | 166 | 0.160 |
Why?
|
| Hispanic Americans | 3 | 2020 | 428 | 0.160 |
Why?
|
| Colonic Polyps | 1 | 2018 | 35 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 195 | 0.150 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 13 | 0.150 |
Why?
|
| Bipolar Disorder | 3 | 2013 | 63 | 0.150 |
Why?
|
| Peer Review | 1 | 2017 | 5 | 0.150 |
Why?
|
| Insulin | 2 | 2016 | 208 | 0.150 |
Why?
|
| Poisson Distribution | 3 | 2016 | 94 | 0.150 |
Why?
|
| Population Surveillance | 3 | 2011 | 271 | 0.150 |
Why?
|
| Middle Ear Ventilation | 2 | 2003 | 5 | 0.150 |
Why?
|
| Geriatric Assessment | 1 | 1997 | 40 | 0.150 |
Why?
|
| Hypersensitivity | 2 | 2015 | 21 | 0.150 |
Why?
|
| Case Management | 1 | 1997 | 37 | 0.150 |
Why?
|
| Disabled Persons | 3 | 2011 | 41 | 0.150 |
Why?
|
| Severity of Illness Index | 7 | 2012 | 476 | 0.150 |
Why?
|
| Vaccine Potency | 1 | 2017 | 5 | 0.150 |
Why?
|
| Medicare Part C | 2 | 2016 | 22 | 0.150 |
Why?
|
| Immunization, Passive | 1 | 2017 | 4 | 0.150 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 36 | 0.150 |
Why?
|
| Research | 1 | 2017 | 73 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2014 | 9 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 320 | 0.140 |
Why?
|
| Multiphasic Screening | 2 | 2007 | 10 | 0.140 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2016 | 5 | 0.140 |
Why?
|
| Myelitis, Transverse | 1 | 2016 | 5 | 0.140 |
Why?
|
| Consumer Behavior | 1 | 2017 | 30 | 0.140 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1996 | 1 | 0.140 |
Why?
|
| Pertussis Toxin | 1 | 1996 | 1 | 0.140 |
Why?
|
| Double-Blind Method | 8 | 2006 | 165 | 0.140 |
Why?
|
| Women's Health | 2 | 2015 | 207 | 0.140 |
Why?
|
| Albuminuria | 2 | 2013 | 41 | 0.140 |
Why?
|
| Self Care | 3 | 2012 | 175 | 0.140 |
Why?
|
| Optic Neuritis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 33 | 0.140 |
Why?
|
| Depressive Disorder, Major | 2 | 2009 | 127 | 0.140 |
Why?
|
| Maternal Age | 3 | 2008 | 80 | 0.140 |
Why?
|
| Safety | 2 | 2013 | 45 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 1997 | 180 | 0.130 |
Why?
|
| Risperidone | 1 | 2016 | 4 | 0.130 |
Why?
|
| Drugs, Generic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2020 | 407 | 0.130 |
Why?
|
| Infant Mortality | 2 | 1997 | 22 | 0.130 |
Why?
|
| Patient Admission | 4 | 2004 | 76 | 0.130 |
Why?
|
| Diphtheria | 1 | 2016 | 14 | 0.130 |
Why?
|
| Causality | 2 | 2013 | 43 | 0.130 |
Why?
|
| Health Priorities | 1 | 2016 | 28 | 0.130 |
Why?
|
| Tetanus | 1 | 2016 | 18 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 8 | 0.130 |
Why?
|
| Smoking | 5 | 2000 | 494 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 44 | 0.130 |
Why?
|
| Intimate Partner Violence | 1 | 2015 | 12 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 35 | 0.130 |
Why?
|
| Haemophilus Infections | 3 | 1992 | 8 | 0.130 |
Why?
|
| Bell Palsy | 2 | 2012 | 17 | 0.130 |
Why?
|
| Health Status | 4 | 2009 | 328 | 0.120 |
Why?
|
| Anxiety | 1 | 2015 | 156 | 0.120 |
Why?
|
| Health Services | 3 | 2006 | 117 | 0.120 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2024 | 17 | 0.120 |
Why?
|
| Laboratories | 3 | 2021 | 23 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 182 | 0.120 |
Why?
|
| Continental Population Groups | 6 | 2021 | 315 | 0.120 |
Why?
|
| Health Status Disparities | 2 | 2021 | 153 | 0.120 |
Why?
|
| Seizures | 1 | 2013 | 30 | 0.110 |
Why?
|
| Nephrotic Syndrome | 1 | 1993 | 6 | 0.110 |
Why?
|
| Antibodies, Bacterial | 5 | 2002 | 38 | 0.110 |
Why?
|
| Angioedema | 1 | 2013 | 7 | 0.110 |
Why?
|
| Medical Informatics Applications | 1 | 2013 | 9 | 0.110 |
Why?
|
| Likelihood Functions | 1 | 2013 | 48 | 0.110 |
Why?
|
| Survival Analysis | 6 | 2013 | 226 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 28 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 2013 | 28 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 392 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 91 | 0.110 |
Why?
|
| Socioeconomic Factors | 7 | 2018 | 673 | 0.110 |
Why?
|
| Data Mining | 2 | 2022 | 20 | 0.110 |
Why?
|
| San Francisco | 4 | 1999 | 68 | 0.110 |
Why?
|
| Hyperlipidemias | 2 | 2010 | 58 | 0.110 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2012 | 11 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 365 | 0.110 |
Why?
|
| Colon | 1 | 2012 | 21 | 0.110 |
Why?
|
| Internet | 2 | 2012 | 243 | 0.100 |
Why?
|
| Attitude to Health | 3 | 2004 | 177 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 109 | 0.100 |
Why?
|
| Models, Structural | 1 | 2012 | 3 | 0.100 |
Why?
|
| Acute Disease | 3 | 2017 | 144 | 0.100 |
Why?
|
| Telemedicine | 2 | 2006 | 184 | 0.100 |
Why?
|
| Encephalitis | 1 | 2011 | 6 | 0.100 |
Why?
|
| Colonic Neoplasms | 2 | 1990 | 157 | 0.100 |
Why?
|
| Life Tables | 2 | 1991 | 11 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 22 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2001 | 21 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2009 | 19 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2012 | 79 | 0.100 |
Why?
|
| Cholesterol | 2 | 2016 | 112 | 0.100 |
Why?
|
| Obstetric Labor Complications | 1 | 1991 | 14 | 0.100 |
Why?
|
| Spouse Abuse | 1 | 2011 | 9 | 0.100 |
Why?
|
| Drug Costs | 2 | 2009 | 40 | 0.100 |
Why?
|
| Program Development | 1 | 2012 | 81 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2008 | 298 | 0.100 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2011 | 3 | 0.100 |
Why?
|
| Social Support | 2 | 2000 | 214 | 0.100 |
Why?
|
| Negativism | 1 | 2011 | 1 | 0.100 |
Why?
|
| Database Management Systems | 1 | 2011 | 15 | 0.100 |
Why?
|
| Patient Transfer | 1 | 1991 | 24 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2001 | 43 | 0.100 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 19 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 1991 | 22 | 0.100 |
Why?
|
| Tympanic Membrane | 1 | 1991 | 1 | 0.100 |
Why?
|
| Otitis Media with Effusion | 1 | 1991 | 4 | 0.090 |
Why?
|
| Appendectomy | 1 | 1990 | 5 | 0.090 |
Why?
|
| Appendicitis | 1 | 1990 | 16 | 0.090 |
Why?
|
| Haemophilus influenzae | 4 | 1992 | 5 | 0.090 |
Why?
|
| Registries | 4 | 2020 | 490 | 0.090 |
Why?
|
| Disease Progression | 3 | 2017 | 271 | 0.090 |
Why?
|
| Linear Models | 2 | 2010 | 243 | 0.090 |
Why?
|
| Epidemiologic Methods | 3 | 2019 | 87 | 0.090 |
Why?
|
| Polysaccharides, Bacterial | 3 | 1992 | 4 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2010 | 127 | 0.090 |
Why?
|
| Reimbursement, Incentive | 1 | 2010 | 31 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2012 | 207 | 0.090 |
Why?
|
| Gestational Age | 4 | 2017 | 119 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 399 | 0.090 |
Why?
|
| Carcinogens | 1 | 1989 | 4 | 0.090 |
Why?
|
| Infant, Low Birth Weight | 2 | 2017 | 37 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2011 | 118 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2010 | 61 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 71 | 0.090 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 10 | 0.080 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2009 | 19 | 0.080 |
Why?
|
| Poverty | 1 | 2010 | 182 | 0.080 |
Why?
|
| Alcohol Drinking | 4 | 2005 | 375 | 0.080 |
Why?
|
| Cholelithiasis | 1 | 1989 | 3 | 0.080 |
Why?
|
| Thyroid Hormones | 1 | 1989 | 8 | 0.080 |
Why?
|
| Suicide, Attempted | 2 | 2007 | 98 | 0.080 |
Why?
|
| Gastrointestinal Agents | 1 | 2008 | 4 | 0.080 |
Why?
|
| Longitudinal Studies | 5 | 2012 | 724 | 0.080 |
Why?
|
| Antibodies, Viral | 2 | 2007 | 65 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2010 | 162 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 21 | 0.080 |
Why?
|
| Appointments and Schedules | 2 | 2006 | 34 | 0.080 |
Why?
|
| Fetal Proteins | 1 | 2008 | 5 | 0.080 |
Why?
|
| Insurance, Medigap | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2014 | 1360 | 0.080 |
Why?
|
| Uric Acid | 1 | 1988 | 11 | 0.080 |
Why?
|
| Sex Factors | 5 | 2012 | 661 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 5 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 1037 | 0.080 |
Why?
|
| Washington | 3 | 1999 | 388 | 0.080 |
Why?
|
| Brain | 1 | 2008 | 46 | 0.080 |
Why?
|
| Community-Acquired Infections | 1 | 2008 | 24 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 2005 | 439 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2007 | 6 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 1997 | 12 | 0.070 |
Why?
|
| Paternal Age | 1 | 2007 | 10 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2007 | 41 | 0.070 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2017 | 59 | 0.070 |
Why?
|
| Urinary Incontinence | 1 | 2007 | 33 | 0.070 |
Why?
|
| Probability | 3 | 2019 | 86 | 0.070 |
Why?
|
| Abdomen | 1 | 2006 | 21 | 0.070 |
Why?
|
| Radiography | 1 | 2006 | 41 | 0.070 |
Why?
|
| Immunity, Herd | 1 | 2006 | 5 | 0.070 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 114 | 0.070 |
Why?
|
| Penicillin Resistance | 1 | 2006 | 1 | 0.070 |
Why?
|
| Insurance Benefits | 1 | 2006 | 15 | 0.070 |
Why?
|
| Medical Audit | 3 | 2011 | 41 | 0.070 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2006 | 27 | 0.070 |
Why?
|
| Adiposity | 1 | 2006 | 67 | 0.070 |
Why?
|
| Suicide | 2 | 2007 | 126 | 0.070 |
Why?
|
| Bacterial Capsules | 2 | 2020 | 7 | 0.070 |
Why?
|
| Menopause | 1 | 1986 | 72 | 0.070 |
Why?
|
| African Continental Ancestry Group | 1 | 2006 | 166 | 0.070 |
Why?
|
| Telecommunications | 1 | 2005 | 2 | 0.070 |
Why?
|
| Personal Health Services | 1 | 2005 | 4 | 0.070 |
Why?
|
| Vaccines, Attenuated | 2 | 2018 | 47 | 0.060 |
Why?
|
| Asian Americans | 1 | 2006 | 182 | 0.060 |
Why?
|
| Premature Birth | 2 | 2017 | 138 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2020 | 272 | 0.060 |
Why?
|
| Hotlines | 1 | 2005 | 16 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2008 | 95 | 0.060 |
Why?
|
| Mass Screening | 3 | 2024 | 690 | 0.060 |
Why?
|
| Hypolipidemic Agents | 3 | 2012 | 44 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 129 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2005 | 10 | 0.060 |
Why?
|
| Sampling Studies | 4 | 2000 | 55 | 0.060 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 2004 | 1 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 5 | 0.060 |
Why?
|
| Thyroxine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Neonatal Screening | 1 | 2004 | 13 | 0.060 |
Why?
|
| Thyrotropin | 1 | 2004 | 8 | 0.060 |
Why?
|
| Social Environment | 1 | 1985 | 90 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2004 | 5 | 0.060 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2024 | 14 | 0.060 |
Why?
|
| Alcoholism | 2 | 2006 | 350 | 0.060 |
Why?
|
| Financing, Personal | 3 | 2010 | 24 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2004 | 226 | 0.060 |
Why?
|
| Lithium Compounds | 1 | 2003 | 2 | 0.060 |
Why?
|
| Antimanic Agents | 1 | 2003 | 3 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2003 | 4 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 1985 | 147 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 624 | 0.060 |
Why?
|
| Cause of Death | 2 | 2017 | 185 | 0.060 |
Why?
|
| Medical Records | 3 | 2009 | 106 | 0.050 |
Why?
|
| Physicians, Family | 1 | 2003 | 47 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 3 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2003 | 48 | 0.050 |
Why?
|
| Decision Making | 4 | 2012 | 204 | 0.050 |
Why?
|
| Total Quality Management | 1 | 2003 | 27 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 53 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2009 | 167 | 0.050 |
Why?
|
| Macrolides | 1 | 2022 | 8 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2009 | 244 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 112 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2003 | 36 | 0.050 |
Why?
|
| Penicillins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2022 | 9 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 4 | 0.050 |
Why?
|
| Models, Organizational | 1 | 2003 | 65 | 0.050 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2017 | 35 | 0.050 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 38 | 0.050 |
Why?
|
| Models, Economic | 2 | 2006 | 22 | 0.050 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2002 | 3 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 21 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 67 | 0.050 |
Why?
|
| Staphylococcal Vaccines | 1 | 2002 | 1 | 0.050 |
Why?
|
| Video Recording | 1 | 2002 | 12 | 0.050 |
Why?
|
| Obstetric Labor, Premature | 1 | 2002 | 10 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2002 | 15 | 0.050 |
Why?
|
| Equipment and Supplies | 2 | 2012 | 5 | 0.050 |
Why?
|
| Direct Service Costs | 2 | 2000 | 10 | 0.050 |
Why?
|
| Pandemics | 1 | 2024 | 292 | 0.050 |
Why?
|
| Mothers | 1 | 2023 | 110 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2022 | 95 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2001 | 61 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2002 | 59 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2002 | 112 | 0.050 |
Why?
|
| Group Practice, Prepaid | 2 | 1999 | 9 | 0.050 |
Why?
|
| Phenelzine | 1 | 2000 | 1 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2020 | 12 | 0.050 |
Why?
|
| Child Health Services | 2 | 2000 | 129 | 0.050 |
Why?
|
| Geography | 1 | 2020 | 41 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 124 | 0.050 |
Why?
|
| Patient Participation | 1 | 2002 | 144 | 0.050 |
Why?
|
| Remote Consultation | 1 | 2000 | 11 | 0.050 |
Why?
|
| Decision Making, Organizational | 1 | 2020 | 4 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 19 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 151 | 0.050 |
Why?
|
| Nurses | 1 | 2000 | 40 | 0.050 |
Why?
|
| Immunosuppression | 2 | 2008 | 9 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Computer Communication Networks | 1 | 2020 | 18 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2000 | 27 | 0.040 |
Why?
|
| Algorithms | 2 | 2013 | 241 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2000 | 23 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2020 | 50 | 0.040 |
Why?
|
| Health Behavior | 2 | 2004 | 374 | 0.040 |
Why?
|
| Health Care Surveys | 3 | 2007 | 247 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 37 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 30 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2019 | 45 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 237 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1990 | 65 | 0.040 |
Why?
|
| Alcohol-Related Disorders | 1 | 2000 | 56 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2012 | 82 | 0.040 |
Why?
|
| Length of Stay | 2 | 1997 | 183 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 155 | 0.040 |
Why?
|
| Medicaid | 1 | 2000 | 211 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 20 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2018 | 13 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2020 | 256 | 0.040 |
Why?
|
| Rectal Neoplasms | 2 | 1990 | 67 | 0.040 |
Why?
|
| State Health Plans | 1 | 2018 | 44 | 0.040 |
Why?
|
| Biological Products | 1 | 2018 | 5 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1998 | 7 | 0.040 |
Why?
|
| Methotrexate | 1 | 2018 | 8 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 28 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 17 | 0.040 |
Why?
|
| Insulin, Long-Acting | 1 | 2017 | 12 | 0.040 |
Why?
|
| Nurse Practitioners | 1 | 1997 | 20 | 0.040 |
Why?
|
| Pupil | 1 | 1997 | 1 | 0.040 |
Why?
|
| Vision Screening | 1 | 1997 | 2 | 0.040 |
Why?
|
| Ethnic Groups | 1 | 2021 | 501 | 0.040 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2017 | 11 | 0.040 |
Why?
|
| Retinal Diseases | 1 | 1997 | 16 | 0.040 |
Why?
|
| Stillbirth | 1 | 2017 | 30 | 0.040 |
Why?
|
| African Americans | 1 | 2020 | 490 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 333 | 0.040 |
Why?
|
| Blood Pressure Determination | 2 | 1999 | 58 | 0.040 |
Why?
|
| Parents | 1 | 2020 | 309 | 0.040 |
Why?
|
| Biomarkers | 2 | 2008 | 308 | 0.040 |
Why?
|
| Health Policy | 1 | 2018 | 136 | 0.040 |
Why?
|
| Bordetella pertussis | 2 | 2012 | 6 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 1996 | 22 | 0.040 |
Why?
|
| Family Health | 1 | 2017 | 49 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 1997 | 95 | 0.040 |
Why?
|
| Medical Record Linkage | 1 | 1997 | 44 | 0.040 |
Why?
|
| Demography | 1 | 1997 | 108 | 0.030 |
Why?
|
| Interviews as Topic | 3 | 2005 | 327 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 269 | 0.030 |
Why?
|
| Hospitals | 1 | 1997 | 80 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 214 | 0.030 |
Why?
|
| Cohort Effect | 1 | 1996 | 4 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 1996 | 20 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 22 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 33 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 29 | 0.030 |
Why?
|
| Outpatients | 2 | 2013 | 111 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2016 | 25 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1996 | 77 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 32 | 0.030 |
Why?
|
| Alcoholic Intoxication | 1 | 1996 | 7 | 0.030 |
Why?
|
| Antihypertensive Agents | 2 | 2009 | 172 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 337 | 0.030 |
Why?
|
| Aging | 1 | 1997 | 165 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 3 | 2006 | 270 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 45 | 0.030 |
Why?
|
| Urban Population | 1 | 1996 | 124 | 0.030 |
Why?
|
| Mortality | 2 | 2006 | 123 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2009 | 150 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 6 | 0.030 |
Why?
|
| Serotyping | 2 | 2007 | 5 | 0.030 |
Why?
|
| Income | 2 | 2005 | 98 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 1989 | 259 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 199 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 1993 | 11 | 0.030 |
Why?
|
| Amides | 1 | 2013 | 4 | 0.030 |
Why?
|
| Fumarates | 1 | 2013 | 5 | 0.030 |
Why?
|
| North Carolina | 1 | 1993 | 34 | 0.030 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2013 | 2 | 0.030 |
Why?
|
| Computer Security | 1 | 2013 | 8 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2013 | 3 | 0.030 |
Why?
|
| Confidentiality | 1 | 2013 | 30 | 0.030 |
Why?
|
| Folic Acid | 2 | 1991 | 35 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 43 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 77 | 0.030 |
Why?
|
| Numbers Needed To Treat | 1 | 2012 | 3 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2013 | 79 | 0.030 |
Why?
|
| Metformin | 1 | 2013 | 61 | 0.030 |
Why?
|
| Blood Pressure Monitors | 1 | 1992 | 3 | 0.030 |
Why?
|
| Vaccines, Acellular | 1 | 2012 | 12 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 157 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 53 | 0.030 |
Why?
|
| Quality of Life | 2 | 2007 | 529 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2012 | 22 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2012 | 52 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 90 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1992 | 2 | 0.030 |
Why?
|
| Diphtheria Toxoid | 1 | 1992 | 4 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2012 | 15 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2012 | 71 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 11 | 0.030 |
Why?
|
| Privacy | 1 | 2012 | 7 | 0.030 |
Why?
|
| Self Administration | 1 | 2012 | 12 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1991 | 3 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 45 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 125 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2001 | 7 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 131 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 20 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 36 | 0.020 |
Why?
|
| Fetal Death | 1 | 1991 | 10 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1991 | 10 | 0.020 |
Why?
|
| Safety Management | 1 | 2011 | 15 | 0.020 |
Why?
|
| Acoustic Impedance Tests | 1 | 1991 | 2 | 0.020 |
Why?
|
| Audiometry | 1 | 1991 | 2 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 93 | 0.020 |
Why?
|
| Hearing Disorders | 1 | 1991 | 3 | 0.020 |
Why?
|
| Wounds and Injuries | 2 | 2005 | 51 | 0.020 |
Why?
|
| Sepsis | 1 | 2001 | 71 | 0.020 |
Why?
|
| Pregnancy Trimester, First | 1 | 1991 | 39 | 0.020 |
Why?
|
| Recurrence | 1 | 1991 | 187 | 0.020 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 19 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 20 | 0.020 |
Why?
|
| Atropa belladonna | 1 | 1989 | 1 | 0.020 |
Why?
|
| Erythromycin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Neomycin | 1 | 1989 | 1 | 0.020 |
Why?
|
| Phenylbutazone | 1 | 1989 | 1 | 0.020 |
Why?
|
| Piperidones | 1 | 1989 | 1 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1989 | 1 | 0.020 |
Why?
|
| Propantheline | 1 | 1989 | 1 | 0.020 |
Why?
|
| Secobarbital | 1 | 1989 | 1 | 0.020 |
Why?
|
| Sulfathiazoles | 1 | 1989 | 1 | 0.020 |
Why?
|
| Plants, Toxic | 1 | 1989 | 3 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 1989 | 4 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 1991 | 97 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1989 | 11 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1989 | 25 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2009 | 7 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 25 | 0.020 |
Why?
|
| West Indies | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 1989 | 3 | 0.020 |
Why?
|
| South America | 1 | 2009 | 5 | 0.020 |
Why?
|
| Central America | 1 | 2009 | 5 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 1989 | 3 | 0.020 |
Why?
|
| Vitamins | 1 | 1989 | 65 | 0.020 |
Why?
|
| Mexico | 1 | 2009 | 20 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 72 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 311 | 0.020 |
Why?
|
| Infliximab | 1 | 2008 | 8 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 87 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1989 | 116 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2008 | 26 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2008 | 18 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2008 | 21 | 0.020 |
Why?
|
| Body Weight | 1 | 1989 | 223 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 14 | 0.020 |
Why?
|
| Asperger Syndrome | 1 | 2007 | 5 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 2007 | 16 | 0.020 |
Why?
|
| Twins | 1 | 2007 | 13 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2007 | 24 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 13 | 0.020 |
Why?
|
| Women's Health Services | 1 | 2007 | 21 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 40 | 0.020 |
Why?
|
| Costs and Cost Analysis | 2 | 1997 | 89 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2007 | 70 | 0.020 |
Why?
|
| Skin | 1 | 1986 | 14 | 0.020 |
Why?
|
| Abdominal Fat | 1 | 2006 | 15 | 0.020 |
Why?
|
| Awareness | 1 | 1986 | 18 | 0.020 |
Why?
|
| World Health Organization | 1 | 2006 | 15 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1986 | 42 | 0.020 |
Why?
|
| Biopsy | 1 | 1986 | 75 | 0.020 |
Why?
|
| Retinol-Binding Proteins | 1 | 1986 | 2 | 0.020 |
Why?
|
| Vitamin A | 1 | 1986 | 15 | 0.020 |
Why?
|
| Information Services | 1 | 2006 | 18 | 0.020 |
Why?
|
| Deductibles and Coinsurance | 1 | 2006 | 31 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2006 | 6 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 47 | 0.020 |
Why?
|
| Estrogens | 1 | 1986 | 73 | 0.020 |
Why?
|
| Pharmaceutical Services | 1 | 2006 | 37 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 96 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2005 | 22 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2006 | 106 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2007 | 153 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 1985 | 6 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 1985 | 13 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2006 | 93 | 0.020 |
Why?
|
| Social Isolation | 1 | 1985 | 16 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 414 | 0.020 |
Why?
|
| Prepaid Health Plans | 1 | 2004 | 22 | 0.020 |
Why?
|
| Infant Welfare | 1 | 2004 | 4 | 0.020 |
Why?
|
| Xerostomia | 1 | 2004 | 1 | 0.020 |
Why?
|
| Sleep Stages | 1 | 2004 | 3 | 0.020 |
Why?
|
| Maternal Welfare | 1 | 2004 | 16 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2004 | 18 | 0.020 |
Why?
|
| Carbamazepine | 1 | 2003 | 4 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 205 | 0.010 |
Why?
|
| Trust | 1 | 2003 | 31 | 0.010 |
Why?
|
| Perception | 1 | 2003 | 59 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 4 | 0.010 |
Why?
|
| Laminectomy | 1 | 2002 | 2 | 0.010 |
Why?
|
| Meningitis | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cost Savings | 1 | 2002 | 25 | 0.010 |
Why?
|
| Sickness Impact Profile | 1 | 2002 | 28 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2002 | 6 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 974 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 100 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 102 | 0.010 |
Why?
|
| Colorado | 1 | 2002 | 211 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2000 | 2 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2000 | 16 | 0.010 |
Why?
|
| Models, Econometric | 1 | 2000 | 11 | 0.010 |
Why?
|
| Random Allocation | 1 | 1999 | 41 | 0.010 |
Why?
|
| Disabled Children | 1 | 2000 | 29 | 0.010 |
Why?
|
| Neisseria meningitidis | 1 | 1999 | 11 | 0.010 |
Why?
|
| Health Surveys | 1 | 2000 | 269 | 0.010 |
Why?
|
| Observer Variation | 1 | 1998 | 40 | 0.010 |
Why?
|
| Laboratories, Hospital | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 1997 | 9 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1997 | 21 | 0.010 |
Why?
|
| Group Practice | 1 | 1997 | 26 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1997 | 23 | 0.010 |
Why?
|
| Fundus Oculi | 1 | 1997 | 4 | 0.010 |
Why?
|
| Life Style | 1 | 2000 | 342 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1998 | 120 | 0.010 |
Why?
|
| Oregon | 1 | 1997 | 222 | 0.010 |
Why?
|
| Clostridium tetani | 1 | 1997 | 1 | 0.010 |
Why?
|
| Corynebacterium diphtheriae | 1 | 1997 | 1 | 0.010 |
Why?
|
| HIV Infections | 1 | 2004 | 695 | 0.010 |
Why?
|
| Software | 1 | 1997 | 21 | 0.010 |
Why?
|
| Methods | 1 | 1996 | 7 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 35 | 0.010 |
Why?
|
| Fees, Medical | 1 | 1994 | 5 | 0.010 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 1994 | 7 | 0.010 |
Why?
|
| Sudden Infant Death | 1 | 1993 | 11 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1992 | 41 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1991 | 47 | 0.010 |
Why?
|
| Child Day Care Centers | 1 | 1991 | 4 | 0.010 |
Why?
|
| Mumps Vaccine | 1 | 1991 | 8 | 0.010 |
Why?
|
| Rubella Vaccine | 1 | 1991 | 9 | 0.010 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 1991 | 4 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1991 | 43 | 0.010 |
Why?
|
| Pentosephosphates | 1 | 1991 | 1 | 0.010 |
Why?
|
| Physicians | 1 | 1992 | 141 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1989 | 5 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1989 | 8 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1989 | 13 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1986 | 5 | 0.000 |
Why?
|
| MMPI | 1 | 1983 | 2 | 0.000 |
Why?
|
| Physical Fitness | 1 | 1983 | 76 | 0.000 |
Why?
|